A survey of the role of gender in family therapy training programs was conducted by the Women's Task Force of the American Family Therapy Association (AFTA) in order to determine the extent to which gender issues were included in the curriculum. Questionnaires were sent to 285 programs in the U.S., Canada, and overseas. Only 19% (n = 55) of the original sample participated, with the East Coast representing the largest proportion of respondents. Findings revealed that the three most frequently addressed gender issues are: 1) the impact of cultural and economic conditions on single, female-headed families; 2) gender issues associated with wife abuse; and 3) an examination of the implications of the therapist's gender in therapy interventions. Only 27 programs identify with a feminist model or have a clearly defined sense of gender awareness. A significant finding associated with the introduction of feminist content was the difficulty of integrating gender issues with major theoretical models. Trainee resistance and lack of faculty awareness were also considered obstacles to including gender in program curriculum.
Introduction: Neurodevelopmental impairment is a major long-term complication for a variable number of extremely low gestation neonates (ELGAN). Rates of survival have increased during the past 2 decades however neuromotor disabilities have not decreased. Objective: The aim of this study was to obtain neurodevelopmental disabilities at 2 years corrected age of infants born in the Marche Region between 24 0/7 and 31 6/7 weeks' gestation from 2010 to 2016. Methods/Design: Retrospective evaluation of two-year follow-up data prospectively collected for all infants born at 24 0/7 to 31 6/7 weeks' gestation admitted to the NICU of the Salesi Children's Hospital, Ancona, from January 2010 to December 2016. Exclusion criteria were major congenital malformations and admission after 48 hours of life. Cognitive (from 2010), motor (from 2010) and language (from 2014) development were assessed with Bayley Scales of Infant and Toddler Development 3rd edition and cerebral palsy was graded with Gross Motor Function Classification System (GMFCS). Visual and hearing data were also collected. Moderate and severe impairment (NDI) was defined as: a GMFCS ≥3, unilateral or bilateral blindness, hearing loss improved or not by aids or a developmental score ≤2 SDS. Results: 630 infants admitted to our NICU in the study period were included. Forty-four (6.9%) died before 24 months of age. Five hundred eighty-six infants were eligible for the follow up. Eighty-eight (15%) were lost (missing data, failed to bring their children/moved away, declined the invitation, untraceable to the telephone call). 498 infants were available for the 2y follow-up. Birth weight was 1194 g ± 356; mean GA 204 days ± 14, 258 (52%) were males. Infants with extreme prematurity (24 0/7-27 6/7) were 132 and 366 were very preterm (28 0/7-31 6/7). Mean cognitive composite (n=489) score was 94±14, motor score (n= 490) 101±13 and language score (n=151) 96±18. Mild visual impairment was present in 15 infants (3%). Any hearing impairment was present in 3 (0.6%), with only 1 severe (bilateral deafness not improved by aids). Cerebral Palsy was diagnosed in 15 infants (3.2%): moderate (GMFCS 3) in 4 (0.8%) and severe (GMFCS 4-5) in 7 (1.4%). Moderate and severe NDI was found in 32 infants (6.4%): 13 extreme preterms and 19 very preterms. Birth weight and gender were significantly associated with overall neurodevelopmental impairment (p=0.030, p=0.002 and p<0.001 respectively), but only gender was associated with moderate-severe outcome (p=0.026). Conclusion: Preterm infants of the Marche Neonatal Network cohort born from 2010 to 2016 had relative low rate of moderate-severe
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.